Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of LSD microdosing in major depressive disorder
ACTRN12623000486628Phase 2Completed
- Sponsor
- The University of Auckland
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lysergide in major depressive disorder (MDD), sponsored by The University of Auckland. Primary endpoints: Percentage of participants completing the dosing regimen and Percentage of attended clinic visits once enrolled. Started Aug 2023; status: completed.
02
Drugs
Lysergide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12623000486628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000486628.